5 citations
,
February 2014 in “Journal of Liquid Chromatography & Related Technologies” Method accurately measures finasteride and tamsulosin in combined drug form.
May 2026 in “Journal of Dermatological Treatment” Patients with alopecia areata prefer treatments that regrow scalp hair quickly over how often they need to take the medication.
38 citations
,
November 2005 in “Epilepsia” Levetiracetam is widely used and generally well-tolerated for treating idiopathic generalized epilepsies, with tiredness as the main side effect.
2 citations
,
January 2017 in “Ciência Rural” A capuchin monkey with a skin infection was successfully treated with itraconazole.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
6 citations
,
September 2011 in “Journal of the American Academy of Dermatology” A man with HIV had an unusual syphilis rash that looked like folliculitis but was cured with penicillin.
January 2023 in “Applied sciences” Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
1 citations
,
January 2015 in “Sexual Medicine Reviews” Current treatments for recurrent ischemic priapism are not well-defined and need more research.
April 2025 in “Turkish Journal of Hematology” Nilotinib may cause gray hair to return to its original color.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
4 citations
,
October 2013 in “PLoS ONE” Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.
October 2025 in “International journal of research and scientific innovation” Lupus pneumonitis can be misdiagnosed as pneumonia or tuberculosis, so consider lupus in similar cases for proper treatment.
49 citations
,
August 2018 in “International Journal of Dermatology” Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
15 citations
,
October 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.
4 citations
,
April 2007 in “Journal of Pediatric Gastroenterology and Nutrition” A liver transplant patient with APECED had a rare VZV recurrence and pneumonia, treated successfully, but later died from other infections.
6 citations
,
May 2024 in “JAAD Case Reports” Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
23 citations
,
June 1950 in “American journal of diseases of children” Aminopterin was somewhat effective in acute lymphoblastic leukemia in children but did not increase survival time.
January 2004 in “Chinese Journal of New Drugs and Clinical Remedies”
3 citations
,
June 1983 in “Archives of Dermatology” Aminopterin effectively improves skin conditions but has toxic side effects that need careful monitoring.
September 2017 in “Griffith Research Online (Griffith University, Queensland, Australia)” Blocking IL-17 can reduce joint inflammation in Ross River Virus infections.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” January 2022 in “Galicia Clínica” Alopecia universalis can be an early sign of HIV.
September 2024 in “International Journal of Applied Pharmaceutics” A reliable method was developed to measure Finasteride and Tadalafil in rat blood.
October 2011 in “The American Journal of Gastroenterology” Esomeprazole can cause hepatitis.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
May 2026 in “Journal of Skin and Sexually Transmitted Diseases” Upadacitinib, a JAK1 inhibitor, has shown efficacy in treating various dermatological conditions, including atopic dermatitis and psoriasis, since its FDA approval for these uses. A comprehensive review of literature from 2015 to 2025 highlights its effectiveness, increasing real-world application, and cost-effectiveness compared to other treatments. The review includes systematic reviews, randomized controlled trials, and real-world studies, focusing on its use in cutaneous disorders while excluding non-dermatological indications and non-English articles. Upadacitinib's recent generic availability in India further supports its expanding role in dermatologic therapy.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.